AN ACT relating to prescription drugs.
SB103 would create a new prescription drug cost-sharing rule for Kentucky health plans. For covered prescription drugs, insurers, pharmacy benefit managers, and other pharmacy benefit administrators could not require an insured to pay more in cost sharing than the drug’s cash price. The bill also requires those entities to count qualifying cash-price payments toward the insured’s cost-sharing obligations, establish written procedures for submitting proof of payment, and include contract terms requiring pharmacies and related vendors to comply. Pharmacies would be expressly allowed to tell insureds about the rule and would have to submit proof of cash-price payments to the insurer.
The bill defines key terms broadly, including “health plan,” “insurer,” “pharmacy,” and “pharmacy benefit manager,” and applies the new requirements to a wide range of coverage types, including fully insured and self-insured plans, limited health service plans, student health plans, Medicare Part D-related coverage, and Medicare Advantage plans. It also adds conforming changes to state statutes governing limited health service organizations, state postsecondary institution health plans, and the state employee health insurance program so that those plans must comply with the new prescription drug provisions. The bill delays application until health plans issued or renewed on or after January 1, 2027, and takes effect the same day.
In addition to the prescription drug provisions, SB103 makes a technical amendment to KRS 315 by creating a new section requiring pharmacies to comply with the proof-of-payment requirement. It also updates several public employee and postsecondary education health plan statutes to incorporate the new drug cost-sharing rules alongside existing mandated benefits and enrollment protections. The bill preserves existing coverage requirements and states that it should not be construed to reduce benefits otherwise required by law.
The overall sentiment in the available record appears neutral to supportive, but there is limited public discussion in the provided materials. There were no recorded votes or committee transcript excerpts, so there is no documented floor debate or formal opposition in the supplied context. The bill’s structure suggests an effort to standardize how prescription drug payments are credited toward deductibles and copays, while preserving exceptions for high-deductible health plans and certain employee plans where federal tax treatment could be affected.
The main points of potential contention are likely to be the cost and administrative burden on insurers, pharmacy benefit managers, and pharmacies, as well as the interaction with federal high-deductible health plan rules and self-insured employer plans. The bill also raises implementation questions about how cash-price payments are verified, how pharmacies must transmit proof, and how the rule applies across different plan types, including Medicare-related coverage and public employee plans.
SB103 would amend Kentucky insurance and health-plan statutes to prohibit cost sharing for covered prescription drugs from exceeding the drug’s cash price, require crediting of qualifying cash payments toward deductibles and other cost-sharing obligations, and mandate insurer procedures and contract terms to implement the rule. It would also add a new pharmacy chapter requirement and conforming references in statutes governing limited health service plans, state postsecondary institution plans, and the state employee health insurance program. The bill affects insurers, PBMs, pharmacies, public employers, and insured consumers, with delayed applicability to plans issued or renewed on or after January 1, 2027.
The available record shows no committee transcript or vote history, so there is no direct evidence of debate or partisan division. Based on the bill text alone, the measure appears consumer-protective and likely intended to reduce out-of-pocket prescription costs, while also imposing new compliance obligations on insurers and pharmacies. The absence of recorded opposition or amendments in the provided materials leaves the overall sentiment best characterized as neutral to mildly favorable.
Likely areas of contention include whether the bill shifts costs or administrative complexity onto insurers, PBMs, and pharmacies; whether the cash-price cap could affect negotiated pricing and plan design; and how the rule interacts with federal law, especially high-deductible health plans and self-insured arrangements. Another possible point of dispute is the breadth of the bill’s coverage, which extends to Medicare-related products and public employee plans, and the operational burden of creating proof-of-payment systems and contract compliance requirements. No specific individuals or groups are identified in the supplied discussion materials, but the affected stakeholders are clearly insurers, PBMs, pharmacies, public employers, and insured patients.